CHINARES PHARMA (03320) announced the annual results for Tasly Pharmaceutical Group Co., Ltd. for the period ending December 31, 2025. The company reported total operating revenue of RMB 8.236 billion, representing a decrease of 3.08% year-on-year. However, net profit attributable to shareholders of the listed company reached RMB 1.105 billion, marking a year-on-year increase of 15.63%. Basic earnings per share were RMB 0.74. The board proposed a cash dividend distribution of RMB 1.00 per 10 shares (tax inclusive).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments